Karo Bio: Interim Report January-September 2013

25-10-2013 Business Wire HealthComments (0)

Karo BioPharmaceutical

Regulatory News: Karo Bio (STO:KARO): The January–September period and the third quarter 2013 in brief · Net sales amounted to MSEK 37.4 (24.6), whereof the third quarter amounted to MSEK 21.2 (8.1) · Net loss for the group was reduced to MSEK 18.7 (89.3), with a profit for the third quarter of MSEK 6.5 (-12.6) · Loss per share was SEK 0.04 (0.23), with a third quarter earnings per share of SEK 0.01 (-0.03) · Cash flow from operating activities was MSEK -25.5

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top